Drug Search Results
More Filters [+]

PBF-677

Alternative Names: pbf-677, pbf677, pbf 677
Latest Update: 2022-01-13
Latest Update Note: Clinical Trial Update

Product Description

Potent and selective, GI-restricted adenosine A3 receptor antagonist as first in class oral treatment for IBD.

Mechanisms of Action: ADORA3 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Palobiofarma SL
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PBF-677

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Colitis, Ulcerative

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2017-003228-54

P2

Active, not recruiting

Colitis, Ulcerative

2019-04-09

Recent News Events